AngioDynamics names Eric Honroth as new CEO, effective Nov. 2026

AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Eric Honroth as President and Chief Executive Officer and as a member of its Board of Directors, effective November 2, 2026, according to a company statement.

Honroth will succeed Jim Clemmer, who is retiring after ten years in the role. Clemmer will depart the Board on November 2, 2026, and will remain in a consulting capacity during the transition period.

Honroth brings more than 20 years of medical device and life sciences experience across cardiovascular, endovascular, urology, and oncology markets. He previously held senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific.

Most recently, Honroth served as Global President, Life Science at Getinge, and previously led Getinge's $1.2 billion North American business.

"Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure," said Howard Donnelly, AngioDynamics Board Chair.

"I am honored to lead AngioDynamics at such an important moment for the Company," Honroth said. "I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value."

The appointment followed a Board-led search focused on finding a candidate with medical technology experience and a record of commercial execution and operational discipline.

You May Also Be Interested In

• Glaukos licenses retinal biologic RO-104 from RevOpsis Therapeutics
• Zeo Energy Corp (ZEO) files $150M mixed shelf
• Brink's gets CMA approval in principle for NCR Atleos deal remedy